Chronic HMGCR/HMG-CoA reductase inhibitor treatment contributes to dysglycemia by upregulating hepatic gluconeogenesis through autophagy induction-Reference-Cited by-同舟云学术

Chronic HMGCR/HMG-CoA reductase inhibitor treatment contributes to dysglycemia by upregulating hepatic gluconeogenesis through autophagy induction

Published:2015-11-02 Issue:11 Volume:11 Page:2089-2101
ISSN:1554-8627
Container-title:Autophagy
language:en
Short-container-title:Autophagy

Author:

Wang Hye Jin¹²³,Park Jae Yeo⁴⁵,Kwon Obin³⁶,Choe Eun Yeong¹²,Kim Chul Hoon³⁶,Hur Kyu Yeon⁷,Lee Myung-Shik⁷⁸,Yun Mijin⁹,Cha Bong Soo¹²³,Kim Young-Bum¹⁰,Lee Hyangkyu⁴⁵,Kang Eun Seok¹²³

Affiliation:

1. Division of Endocrinology and Metabolism; Department of Internal Medicine; Yonsei University College of Medicine; Seoul, Korea

2. Institute of Endocrine Research; Yonsei University College of Medicine; Seoul, Korea

3. Brain Korea 21 PLUS Project for Medical Science; Yonsei University College of Medicine; Seoul, Korea

4. Department of Clinical Nursing Science; Yonsei University College of Nursing; Seoul, Korea

5. Nursing Policy and Research Institute; Biobehavioral Research Center; Yonsei University; Seoul, Korea

6. Department of Pharmacology; Yonsei University College of Medicine; Seoul, Korea

7. Department of Medicine; Samsung Medical Center; Sungkyunkwan University School of Medicine; Seoul, Korea

8. Samsung Advanced Institute for Health Sciences and Technology; Sungkyunkwan University School of Medicine; Seoul, Korea

9. Department of Nuclear Medicine; Yonsei University College of Medicine; Seoul, Korea

10. Division of Endocrinology, Diabetes, and Metabolism; Department of Medicine; Beth Israel Deaconess Medical Center and Harvard Medical School; Boston, MA USA

Publisher

Informa UK Limited

Subject

Cell Biology,Molecular Biology

Link

https://www.tandfonline.com/doi/pdf/10.1080/15548627.2015.1091139

Reference48 articles.

1. Heart Protection Study

2. Reduction in Cardiovascular Events With Atorvastatin in 2,532 Patients With Type 2 Diabetes

3. Rosuvastatin in Older Patients with Systolic Heart Failure

4. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Short‐Term Statin Therapy Induces Hepatic Insulin Resistance Through HNF4α/PAQR9/PPM1α Axis Regulated AKT Phosphorylation;Advanced Science;2024-07-05

2. Role of Gut Microbiota in Statin-Associated New-Onset Diabetes—A Cross-Sectional and Prospective Analysis of the FINRISK 2002 Cohort;Arteriosclerosis, Thrombosis, and Vascular Biology;2024-02

3. Statins and risk of type 2 diabetes: mechanism and clinical implications;Frontiers in Endocrinology;2023-09-19

4. Some pleiotropic effects of statins on hepatocellular carcinoma cells: Comparative study on atorvastatin, rosuvastatin and simvastatin;Advances in Medical Sciences;2023-09

5. Anti-Obesity Effects of Menthae Herba Hydrosol on High-Fat Diet Induced Obese Mice;Journal of Korean Medicine Rehabilitation;2023-07-31